Abstract
MicroRNA (miRNA) processing is a critical step in mature miRNA production. Its dysregulation leads to an increase in miRNA isoforms with heterogenous 5′-ends (isomiRs), which can recognize distinct target sites because of their shifted seed sequence. Although some miRNA genes display productive expression of their 5′-isomiRs in cancers, how their production is controlled and how 5′-isomiRs affect tumor progression have yet to be explored. In this study, based on integrative analyses of high-throughput sequencing data produced by our group and publicly available data, we demonstrate that primary miR-21 (pri-miR-21) is processed into the cancer-specific isomiR isomiR-21-5p | ±1, which suppresses growth hormone receptor (GHR) in liver cancer. Treatment with antagomirs against isomiR-21-5p | ±1 inhibited the in vitro tumorigenesis of liver cancer cells and allowed the recovery of GHR, whereas the introduction of isomiR-21-5p | ±1 mimics attenuated these effects. These effects were validated in a mouse model of spontaneous liver cancer. Heterogeneous nuclear ribonucleoprotein C and U2 small nuclear RNA auxiliary factor 2 were predicted to bind upstream of pre-miR-21 via a poly-(U) motif and influence Drosha processing to induce the production of isomiR-21-5p | ±1. Our findings suggest an oncogenic function for the non-canonical isomiR-21-5p | ±1 in liver cancer, and its production was shown to be regulated by hnRNPC.
Similar content being viewed by others
Introduction
MicroRNAs (miRNAs) are short, ~22 nucleotide (nt), single-stranded RNAs that are involved in post-transcriptional and translational gene regulation via base pairing between their seed sequences (nt 2–7 from the 5′-end of the miRNA) and the 3′-untranslated region (3′-UTR) of their target mRNAs1. As seed pairing is critical for the recognition of miRNA targets, precise miRNA processing is necessary to obtain an exact seed sequence. Dysregulation of processing leads to shifts in the seed sequence and rewiring of the miRNA-target network2,3,4,5.
Two RNase III-type enzymes, Drosha and Dicer, are major factors that participate in the miRNA maturation process, and recognition motifs for these enzymes in primary miRNA transcripts (pri-miRNAs) and precursor miRNAs (pre-miRNAs) have been found to be critical for efficient and accurate miRNA processing6,7. Drosha preferentially recognizes a local hairpin structure consisting of an ~35 base pair (bp) stem between a ≥ 10-nt apical loop and a dangling single-strand region (basal segment)8,9,10. Drosha then makes a staggered cut to leave a 2-nt 3′ overhang ~13 bp away from the basal junction and/or ~22 bp away from the apical junction8,11,12. The basal UG and the apical UGU/GUG motif help orient the microprocessor complex on the pri-miRNA and support efficient processing8,13,14. The CNNC motif in the 3′ basal segment10,13,15 and the mismatched GHG (mGHG) motif in the basal stem9,16 enhance Drosha processing, and the position of these motifs affects the Drosha cleavage site. Recently, in addition to the sequence motifs, structural elements, such as the flexibility of the basal stem17 and the position of a bulge on the stem10, have also been found to modulate Drosha processing efficiency and accuracy. In contrast, the Dicer processing site is known to be determined by measuring ~22 bp from the 3′-end of the pre-miRNA (3′-counting rule)18,19 or from the 5′-end (5′-counting rule)20, or ~2 bp from the terminal/internal loop (loop-counting rule)21. However, both the 3′- and 5′-counting rules for Dicer processing are largely dependent on the prior Drosha processing position. After processing, miRNAs interact with Argonaute (Ago) proteins to form RNA-induced silencing complexes. Because Ago loading and target selection by the Ago-miRNA complex are also dependent on the 5′-end of the miRNA1,22, Drosha processing is a critical step for cognate target recognition by miRNAs in cells.
miRNA isoforms (isomiRs) with 5′-ends that differ from those of canonical miRNAs have been considered to be simple byproducts of miRNA processing, but recent reports have shown that they also have unique biological functions2,3,4,5. These isomiRs tend to be expressed specifically enough to distinguish between various cancer types based on their expression23, and some coordinate with their canonical miRNAs to regulate genes in common biological pathways3. For example, along with miR-140-3p, its isomiR, isomiR-140-3p, has a tumor-suppressive function in breast cancer by repressing cellular proliferation and migration5. However, although there are a few reports that isomiRs have functional relevance in cancer, how cancer-related isomiRs are specifically regulated and how they rewire the regulatory network to confer malignant properties on cancer cells are topics that have not yet been explored.
To comprehensively examine isomiR expression during cancer progression, we measured relative isomiR expression across various liver hepatocellular carcinoma (LIHC) datasets. While isomiR expression relative to canonical miRNA expression, henceforth referred to as the isomiR ratio, remained consistent in most cases, some isomiRs exhibited significant dysregulation in hepatocellular carcinoma (HCC) compared to non-cancerous control (non-tumor) tissues, suggesting that trans-acting factors may affect the biogenesis of isomiRs. Here, we present isomiRs of miR-21-5p (isomiR-21-5p | ±1) as potent oncomiRs that systemically inhibit the growth hormone receptor (GHR) and lead to the malignant transformation and growth of liver hepatocyte cells. Moreover, we demonstrate that heterogeneous nuclear ribonucleoprotein C (hnRNPC) physically interacts with primary miR-21 (pri-miR-21) to induce isomiR-21-5p | ±1, highlighting the potential therapeutic value of targeting the hnRNPC-isomiR-21-5p | ±1 regulatory axis in the treatment of liver cancer.
Materials and methods
Patient enrollment
Patient samples were collected at the Catholic University Hospital. The study protocol was approved by the institutional review board of the Catholic University Hospital. All investigations performed in the present study were conducted in accordance with the guidelines of the 1975 Declaration of Helsinki.
The study subjects were allocated to one of two groups: healthy controls (n = 15) and HCC patients (n = 62). Healthy individuals and patients were not randomized to conduct an observational study. Healthy controls were defined as individuals aged between 18 and 50 years. HCC was diagnosed if the tumor had a maximum diameter of >1 cm and characteristic features of HCC (arterial phase hyperenhancement, washout in the portal venous or delayed phase, threshold growth, and capsule appearance) on multiphase computed tomography and/or magnetic resonance imaging. If these criteria were present but there was a lack of diagnostic certainty, a liver biopsy was performed to confirm the diagnosis of HCC24. Two patient samples were excluded from the analysis because of their poor RNA-seq quality.
Data sources
GRCh37 was used as the reference genome, GENCODE v19 (Dec-05-2013, based on GRCh37) was used for protein-coding gene annotations, and miRBase v21 (lifted over to GRCh37) was used for miRNA annotations. To acquire liver-specific 3′-UTR annotations and to measure mRNA expression levels, the 3′-UTRs were updated with the major form from profiled 3P-seq data from Huh7 cells (GSE52531)25. Public RNA-seq and miRNA-seq datasets from the TCGA_LIHC cohort were downloaded from the data portal of Genomic Data Commons (GDC), and those from the Tsinghua_LIHC cohort were downloaded from GSE7727626. To conduct pan-cancer analysis of GHR, gene expression and clinical information tables for 16 types of cancer were downloaded from the GDC portal, each with at least 10 nontumor and 10 cancer samples.
qRT–PCR
Total RNA was isolated using TRIzol reagent (Invitrogen). RNA was converted to cDNA using a miScript II RT Kit (Qiagen). Reverse transcription (RT) was performed as follows: 4 µL miScript RT Reaction Buffer, 2 µL miScript RT Enzyme Mix, 2 µL miScript Nucleics Mix, and 12 µL template RNA (500 ng). The RT cycling protocol consisted of 60 min at 37 °C, 5 min at 95 °C, and cooling at 4 °C. cDNA samples were stored at -20 °C. qRT–PCR was performed using the SensiFAST SYBR No-ROX kit (Bioline), and the list of primers is shown in Supplementary Table 3. For each miRNA target, the cDNA was diluted at a ratio of 1:50. The cycling program consisted of the following: first step 10 min at 95 °C, second step (40 cycles) of denaturation (10 s at 95 °C), annealing (10 s at 58 °C), and extension (30 s at 72 °C). A Tetro cDNA synthesis kit (Bioline) was used for qRT–PCR. The RT reaction was performed as follows: 4 µL RT Reaction Buffer, 1 µL Tetro RT Enzyme, 1 µL Oligo dT, 1 µL dNTP mix, and 12 µL template RNA (1 µg). The RT cycling protocol consisted of 60 min at 37 °C, 5 min at 85 °C, and cooling at 4 °C. cDNA samples were stored at -20 °C. qRT–PCR was performed using the SensiFAST SYBR No-ROX kit (Bioline), and the list of primers is shown in Supplementary Table 4. For each mRNA target, the cDNA was diluted at a ratio of 1:20. The cycling program consisted of the first step 10 min at 95 °C and the second step cycling (40 cycles) of denaturation (10 s at 95 °C), annealing (10 s at 62 °C (GHR, GADD45G), 63.3 °C (RGS18, GPR65)), and extension (60 s at 72 °C). Raw Cq values were obtained using BioRad CFX software. The level of U6 snRNA or GAPDH expression was used as the loading control, and the relative expression levels were normalized to the control: 2−(Target Ct − Control Ct).
Cell culture and transfection
The Hep3B, HepG2, Huh7, PLC/PRF/5, SNU-182, SNU-354, SNU-368, SNU-387, SNU-423, SNU-449, and SNU-475 HCC cell lines were acquired from the Korean Cell Line Bank. The normal liver cell line MIHA was kindly provided by Dr. Roy-Chowdhury (Albert Einstein College of Medicine). All cell lines were maintained in RPMI-1640, DMEM, or EMEM supplemented with 10% fetal bovine serum and 100 units/mL penicillin/streptomycin (GenDepot). All cells were cultured at 37 °C in a humidified incubator with 5% CO2.
Small interfering RNAs (siRNAs) were synthesized by Genolution (Seoul, Korea), antisense antagomirs were purchased from BIONEER (Daejeon, Korea), and 100 nM siRNA was transfected into liver cancer cells. The siRNA or antagomir sequences are listed in Supplementary Table 4. Human hnRNPC and U2AF2 expression plasmids and subcloned gene ORF sequences were purchased from GenScriptTM (Piscataway, NJ, USA). Transfections were carried out using Lipofectamine RNAiMAX or Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions.
Quantification and statistical analysis
DEG analysis between two groups was performed using the Wilcoxon rank-sum test for unpaired data and the Wilcoxon signed rank-sum test for paired data with the mannwhitneyu function in the Python Scipy package. Pearson correlation coefficients were calculated using the Pearsonr function in the Python Scipy package. Univariate and multivariate analyses of survival differences between the two patient groups, divided by the median expression level, were conducted using the survival package in R. Cox proportional hazard ratios were calculated using the coxph function, and P values were estimated using the Wald test. Multivariate linear regression was performed using the R built-in function ′lm′ after min-max scaling of all variables to facilitate the comparison of coefficients. Multiple hypothesis correction was performed using Benjamini–Hochberg FDR correction. All quantitative experiments were reported with data from three independent biological replicates, and the results are presented as the mean ± SEM. Statistical comparisons between two groups were performed using an unpaired Student’s T test.
Results
IsomiR expression in non-tumor hepatocytes and HCCs
To identify cancer-specific isomiR signatures, we initially processed our multi-stage HCC data (Catholic_LIHC) and publicly available liver cancer miRNA sequencing datasets obtained from The Cancer Genome Atlas liver HCC project (TCGA_LIHC) and the Gene Expression Omnibus (GEO) of the National Center for Biotechnology Information (NCBI) (GSE77276, Tsinghua_LIHC) (Fig. 1a). Data were mapped to hairpin precursor sequences in miRBase (version 21) using miRDeep227, which was subjected to our computational pipeline (Fig. 1b and Supplementary Table 1; see Methods for more details). Because differences in the 5′- but not 3′-ends of the isomiRs shifted seed sequences and altered target mRNAs, mapped reads with 3′-end offsets were collapsed to the same miRNAs/isomiRs (Fig. 1b). Eighteen miRNAs that were found to be dominantly processed at their 5′-ends differently than previously annotated in miRBase were accordingly updated with the new 5′-end, and the original miRNAs were treated as isomiRs (Supplementary Fig. 1a and Supplementary Table 2). Collectively, 619 miRNAs and 518 isomiRs (from 466 miRNA loci) with ≥ 1 reads per million mapped reads (RPM) were detected in at least seven samples from Catholic_LIHC cohorts. The majority of the isomiR 5′-ends were offset ± by 1 nt from the canonical 5′-ends (Fig. 1c), whereas 18% of the isomiRs had 5′-ends that were offset by more than ±1 nt. IsomiRs accounted for approximately 45% of all detected miRNAs (Fig. 1d, inset), and 10 isomiRs were ranked within the top 100 most abundant miRNAs (Fig. 1d), suggesting that isomiRs should be taken into account in miRNA studies, as they could play roles that are just as pivotal as those of canonical miRNAs in pathogenic conditions such as cancer.
IsomiR expression levels tended to be highly correlated with those of the corresponding miRNAs in general, as they were processed from the same pri-miRNAs (Supplementary Fig. 1b). However, some miRNA genes appeared to generate more isomiRs than others, even though the corresponding miRNAs were expressed at similar levels (Fig. 1e). Additional analyses showed that the isomiR ratio varied by miRNA in all tested cohorts (Fig. 1f and Supplementary Fig. 1c–f).
Identification and characterization of liver cancer-specific isomiRs
Given these observations, we hypothesized that the isomiR level could be attributed not only to the pri-miRNA level but also to the isomiR production rate. To understand how the isomiR production rate affects the isomiR level, the normalized reads per million (RPM) numbers of isomiRs were regressed with those of miRNAs and the isomiR ratios using multivariate linear regression. The isomiR ratio was significantly correlated with the isomiR level (Supplementary Fig. 2a; coefficient = 0.037; coefficient = 0.014; coefficient = 0.065 in Catholic_LIHC, TCGA_LIHC, and Tsinghua_LIHC, respectively; P < 2 × 10−16 in all cohorts). We examined (possible) sources of isomiR ratio variation, and it appeared that the isomiR ratios were highly variable across miRNA genes but remained mostly stable across different cohorts (Supplementary Fig. 2b; r ≥ 0.91), indicating that the isomiR production rate is mostly determined by intrinsic factors (sequence and structure) of miRNA genes, as previously reported for in vitro studies9,16. For example, the mir-122 gene produced few isomiRs (< 0.1%) in all three cohorts, whereas the mir-192 gene generated abundant isomiRs (29–41%) (Supplementary Fig. 2b, c).
We then determined the specific isomiRs that were differentially regulated in liver cancer. We compared the ratios of the first and second most abundant isomiRs derived from a given miRNA in non-tumor and HCC samples and found that the ratios were mostly constant (Fig. 2a). This finding indicates that the production rate of most isomiRs is maintained in HCCs. However, the ratios of 25 isomiRs (~10% of commonly profiled isomiRs from the miRNA-seq datasets) were repeatedly found to differ between non-tumor and HCC samples in all cohorts (Fig. 2a), suggesting context-dependent regulation of isomiR production in HCCs. For instance, mir-21 produced relatively more isomiR-21-5p | +1 and isomiR-21-5p | -1 in tumor tissues than in non-tumor tissues (false discovery rate, FDR, < 3.74 × 10−4; FDR < 5.61 × 10−8, respectively; one-way ANOVA test). Taken together, these results indicate that although isomiR production rates seem to be dominantly regulated by the cis-acting elements of miRNAs, some can be modulated by cellular context-dependent factors, such as trans-acting elements.
Clinically relevant isomiR-21-5p | ±1
We further prioritized the isomiRs by inspecting differentially expressed genes (DEGs) and their association with clinical information (Supplementary Fig. 7a). Of the eight isomiRs whose levels appeared to be significantly changed in HCC across cohorts (Fig. 2b), three isomiRs (isomiR-103a-3p | +2, isomiR-21-5p | +1, and isomiR-21-5p | -1) were associated with overall patient survival rates (P ≤ 0.05, for at least one dataset, Wald test) (Supplementary Fig. 2d). The expression levels of isomiR-103a-3p | +2 were relatively low (Supplementary Fig. 2e) compared to those of both isomiR-21-5p | ±1, which exhibited significant overexpression and an increase in the isomiR ratio in HCC (Fig. 2c, d). Both isomiR-21-5p | ±1 levels were significantly associated with the overall survival rates (Fig. 2e; P ≤ 0.05, Wald test). High miR-21-5p expression was also associated with a poor survival rate in patients with liver cancer, implying that the clinical relevance of isomiR-21-5p | ±1 may come from that of miR-21-5p (Supplementary Fig. 2f). To partly overcome the collinearity problem between the expression of isomiR-21-5p | ±1 and miR-21-5p (Supplementary Fig. 2g), survival analysis was performed using the isomiR ratio rather than the expression levels. Patients with liver cancer with high isomiR ratios exhibited marginally worse survival rates, indicating that isomiR-21-5p | ±1 and miR-21-5p had independent clinical relevance (Fig. 2f).
IsomiR-21-5p | ±1 function as an oncomiR in liver cancer
We assessed the endogenous expression levels of isomiR-21-5p | ±1 in liver cancer cell lines and immortalized normal hepatocytes (MIHA and L-02). Two liver cancer lines, SNU-182 and SNU-368, exhibited relatively high expression of isomiR-21-5p | +1 compared to MIHA and L-02 (Fig. 3a, top), whereas the liver cancer lines SNU-354 and PLC/PRF/5 exhibited high isomiR-21-5p | -1 expression (Fig. 3a, bottom). Next, we introduced mimics of isomiR-21-5p | ±1 into liver cancer cells expressing relatively low levels of isomiR-21-5p | ±1 [Hep3B and Huh7 (both mimics individually introduced), SNU-423 (isomiR-21-5p | +1 mimic), and SNU-398 (isomiR-21-5p | -1 mimic)]. The expression of each isomiR-21-5p | ±1 was successfully measured in liver cancer cells and was distinguished from that of miR-21-5p (Supplementary Fig. 3a, b).
Interestingly, we found that isomiR-21-5p | ±1 is produced with different 3′-ends in a manner that is partly dependent on the 5′-end (Fig. 3b), which was previously reported as the 5′-counting rule of Dicer20. Therefore, to reduce possible experimental bias, we designed primers for the major 3′-ends to determine isomiR expression levels. We examined whether isomiR-21-5p | ±1 was downregulated by antisense isomiR-21-5p | ±1 (AS-isomiR-21-5p | -1 and AS-isomiR-21-5p | +1). Treatment with either form of antisense led to targeted disruption of the indicated versions of isomiR-21-5p | ±1 in HepG2 liver cancer cells, which normally express both isomiR-21-5p | ±1 at high levels (Fig. 3c). Similarly, treatment with AS-isomiR-21-5p | +1 reduced the levels of endogenous isomiR-21-5p | +1 in SNU-182 and SNU-368 cells, which normally express isomiR-21-5p | +1 at high levels, whereas treatment with AS-isomiR-21-5p | -1 reduced the levels of endogenous isomiR-21-5p | -1 in PLC/PRF/5 and SNU-354 cells, which normally express isomiR-21-5p | -1 at high levels (Supplementary Fig. 3c, d). Therefore, we assessed the biological role of isomiR-21-5p | ±1 in the development and progression of liver cancer using these antisense constructs.
To verify the oncogenic function of isomiR-21-5p±1 in liver carcinogenesis, we performed an MTT assay. The introduction of AS-isomiR-21-5p | +1 into cells that highly expressed isomiR-21-5p | +1 (SNU-182 and SNU-368) significantly suppressed tumor cell growth rates (Fig. 4a). Similarly, treatment of cells that highly express isomiR-21-5p | -1 (PLC/PRF/5 and SNU-354) with AS-isomiR-21-5p | -1 led to an anti-growth effect, similar to the treatment of HepG2 cells that express both isomiR-21-5p | ±1 at high levels, with either AS-isomiR-21-5p | +1 or AS-isomiR-21-5p | -1 (Fig. 4b, c).
Next, to validate our in vivo observations, Ras-Tg mice that spontaneously developed HCC at approximately 15 weeks of age were established28. Murine mir-21a expressed both isomiR-21a-5p | +1 and isomiR-21a-5p | -1 in liver tissue (Supplementary Fig. 4a). Mice were injected with AS-isomiR-21a-5p | ±1 intravenously with the liver-specific delivery reagent Invivofectamine weekly starting at 13 weeks of age. Liver cancer was detected in the mice using ultrasonography starting at 17 weeks of age (Fig. 4d). Liver cancer masses were detectable starting at 17 weeks of age in the negative control group (N.C), in which four of the five mice developed multiple, large liver cancers. However, liver cancer occurred in only two of the four mice, in which isomiR-21-5p | ±1 levels were reduced (Supplementary Fig. 4b, c). Suppression of isomiR-21a-5p |±1 was observed in the groups treated with AS-isomiR-21a-5p | ±1 (Fig. 4e).
Aberrantly upregulated hnRNPC induces isomiR-21-5p | ±1 in liver cancer
Previous studies have reported that several sequence and structural motifs, such as CNNC, mGHG, basal UG, and basal junction, affect the specificity of Drosha cleavage sites as well as miRNA processing efficiency9,15,16. As expected, we found that most of these motifs were significantly associated with isomiR ratios (Supplementary Fig. 5a–d). However, as the cis-acting elements were neither mutated nor edited in our HCC samples (data not shown), we suspected the involvement of trans-acting elements, such as RNA-binding proteins (RBPs), which can affect the production of isomiRs depending on the pathological condition. RBP binding to the pri-miRNA could alter the secondary structure of the pri-miRNA or destabilize microprocessor binding, possibly resulting in the alteration of Drosha cleavage sites. Notably, an analysis of RBPs in the HepG2 liver cancer cell line using eCLIP-seq data29 identified 10 RBPs that bind to the precursor miR-21 (pre-miR-21-5p) and its flanking region (Fig. 5a). The levels of U2AF2 and hnRNPC appeared to be significantly correlated with the isomiR ratio in all the tested cohorts (FDR < 0.001). To exclude the possibility that the association was due to other factors, such as the level of the host transcript, VMP1, or miR-21-5p, we performed multivariate analysis. The levels of U2AF2 and hnRNPC exhibited a significant relationship with the isomiR-21-5p | ±1 ratio (P < 0.01; Supplementary Fig. 5e, f). Moreover, both RBPs were consistently overexpressed in the tested cohorts, except for U2AF2 in Catholic_LIHC (Supplementary Fig. 5g). Therefore, we hypothesized that hnRNPC and/or U2AF2 binding to pri-miR-21 modulates the Drosha cleavage sites in pri-miR-21 to produce more isomiR-21-5p | ±1 in liver cancer.
To validate this hypothesis, we used RNA interference to knockdown hnRNPC and U2AF2 expression in liver cancer cells, after which miR-21-5p and isomiR-21-5p | ±1 expression levels were measured. Both the isomiR-21-5p | ±1 level and isomiR ratio were significantly reduced in both hnRNPC and U2AF2 knockdown cells compared to controls in all tested liver cancer cell lines (Fig. 5b and Supplementary Fig. 5h, i, m–o). To better understand these results, an hnRNPC overexpression construct was introduced into liver cancer cells along with a pri-miR-21-expressing plasmid, after which changes in miR-21-5p and isomiR-21-5p | ±1 levels were examined. As expected, hnRNPC overexpression caused an increase in both isomiR-21-5p | ±1 expression and the isomiR ratio in all tested liver cancer cell lines (Fig. 5c and Supplementary Fig. 5j–l). The results were similar in U2AF2- and hnRNPC-overexpressing cells, but slightly less significant changes were associated with U2AF2 overexpression (Supplementary Fig. 5p–s). These results suggest that hnRNPC plays an important role in the processing of isomiR-21-5p | ±1 in liver carcinogenesis.
An hnRNPC-isomiR-21-5p | ±1 regulatory axis contributes to liver carcinogenesis
In general, hnRNPC binds to a wide region of RNA that is approximately 230 nt in length30,31,32. Therefore, to validate the regulatory roles of hnRNPC in inducing isomiR-21-5p | ±1 in liver carcinogenesis, we constructed pri-miR-21 expression plasmids containing random mutations in four different poly-(U) regions of pri-miR-21, known as hnRNPC binding motifs (Fig. 6a). Hep3B cells, which exhibited relatively low expression of both endogenous isomiR-21-5p | ±1, were transfected with wild-type (wt) pri-miR-21- or mutated pri-miR-21 (mt#1–4)-expressing plasmids in the presence or absence of FLAG-tagged hnRNPC overexpression. First, we performed hnRNPC immunoprecipitation in cells transfected with wt pri-miR-21-expressing plasmids and determined the levels of pri-miR-21 and/or pre-miR-21 in the immunoprecipitated materials using three different sets of primers (Fig. 6a and Supplementary Fig. 6a). As expected from the eCLIP-seq results (Fig. 5a), hnRNPC bound to pri-miR-21 rather than pre-miR-21. Immunoprecipitation was also performed in cells transfected with mutated pri-miR-21-expressing plasmids, and the results showed that all mutations attenuated hnRNPC binding to pri-miR-21 (Fig. 6b). In addition, the same mutant-transfected cells exhibited reduced amounts of both isomiR-21-5p | ±1 compared to the wt-transfected cells (Figs. 5c, 6c). Moreover, the isomiR ratios for the same cells showed no significant changes compared with those in the corresponding control, with the exception of the isomiR-21-5p | +1 ratio in cells expressing the mt#1 construct (Fig. 6d).
To validate the existence of an hnRNPC-isomiR-21-5p | ±1 regulatory axis in liver carcinogenesis, liver cancer cells were treated with short interfering RNAs targeting hnRNPC (sihnRNPCs) followed by treatment with isomiR-21-5p | ±1 mimics. As shown in Fig. 6e, the anti-growth effect of hnRNPC inhibition was mostly rescued by the introduction of isomiR-21-5p | ±1 mimics in all the tested liver cancer cell lines. These results indicate that aberrant upregulation of hnRNPC induces isomiR-21-5p | ±1 during liver carcinogenesis and contributes to the malignant transformation and growth of non-cancerous hepatocytes.
Cancer-related targets of isomiR-21-5p | ±1
Of the 13,143 mRNAs commonly profiled from the RNA-seq datasets, 3,049 cancer-related mRNAs were selected using gene ontology (GO) analysis (Supplementary Fig. 7a). We further prioritized the genes by inspecting differentially expressed genes (DEGs) and their association with clinical information. Of the 534 mRNAs whose levels appeared to be significantly changed in HCC across cohorts, 187 mRNAs were associated with overall patient survival rates (P ≤ 0.05, for at least one dataset, Wald test).
We then predicted target genes regulated by isomiR-21-5p | ±1 in liver cancer using TargetScan v7.033. Of the 187 mRNAs, 14 were identified as putative targets of isomiR-21-5p | ±1 with at least one target site (6-mer sites with less than -0.1 weighted context ++ score or other canonical site types34,35,36,37) (Supplementary Fig. 7b). Because both isomiR-21-5p | ±1 displayed positive effects on cell growth, of the clinically relevant isomiR-21-5p | ±1 targets, we focused on RGS18, GADD45G, GPR65, and GHR, which contain target sites for both isomiR-21-5p | +1 and isomiR-21-5p | -1 in the 3′-UTR (Supplementary Fig. 7c). First, the introduction of isomiR-21-5p | +1 or isomiR-21-5p | -1 mimics in cells with low isomiR-21-5p | ±1 expression consistently suppressed GHR expression, whereas treatment with AS-isomiR-21-5p | +1 or AS-isomiR-21-5p | -1 significantly induced GHR expression in cells with high isomiR-21-5p |±1 expression (Fig. 7a, b). These manipulations led to varied results for RGS18, GADD45G, and GPR65 in the same experiments (Supplementary Fig. 7d–i). To validate the specificity and selectivity of isomiR-21-5p | +1 and isomiR-21-5p | -1 targeting GHR, we constructed two different psiCHECK-2-GHR-3′-UTR vectors containing either the isomiR-21-5p | +1 site (GHR-3′-UTR#1) or both isomiR-21-5p | ±1 sites (GHR-3′-UTR#2) downstream of a luciferase reporter gene (Fig. 7c) and transformed them into liver cancer cells. As expected, treatment with AS-isomiR-21-5p | ±1, but not with AS-miR-21-5p, significantly augmented luciferase activity (relative to the activity of a second luciferase expressed from the vector) in an isomiR target sequence-specific manner in all tested liver cancer cells (Fig. 7d and Supplementary Fig. 7j, k). The selective regulation of GHR by isomiR-21-5p | ±1 was further validated by Western blot analysis (Fig. 7e). GHR expression was suppressed by the introduction of AS-isomiR-21-5p | +1 or AS-isomiR-21-5p | -1 into HepG2 cells, in which both isomiR-21-5p | ±1 were highly expressed and selectively suppressed by treatment with mimics of either isomiR-21-5p | +1 or isomiR-21-5p | -1 but not by treatment with miR-21-5p. Moreover, murine Ghr also includes target sites for isomiR-21a-5p | ±1 but not for miR-21a-5p, similar to the situation in humans (Fig. 7f). Western blot analysis confirmed elevated Ghrs expression in mouse liver tissues in the groups treated with AS-isomiR-21a-5p | ±1 (Figs. 4d, 7g).
Discussion
IsomiRs, characterized by variation at the 3′- and/or 5′-end(s) of canonical miRNAs, can be created either by imprecise processing by Drosha or Dicer or through the addition or removal of nucleotides at the 3′-end during miRNA biogenesis38. Although the relationship between isomiR expression and disease progression is not yet clearly understood, it has been reported that isomiRs might act as regulatory molecules and are associated with target mRNA repression3. In this study, we provide a systematic view of the molecular signatures of liver cancer-specific isomiRs and identify isomiR-21-5p | ±1 as a potent pro-tumorigenic isomiR in the development of liver cancer. This observation, for the first time, demonstrates an underlying mechanism by which hnRNPC causes isomiR-21-5p | ±1, which can inactivate GHR, contributing to the malignant transformation and growth of tumor cells in hepatocarcinogenesis.
miRNA sequencing studies have shown that 5′- and 3′-isomiRs are widespread and represent approximately 50% of miRNA copies in cells and tissues39. Because the 5′-end of a miRNA determines its seed sequence, 5′-isomiRs have an altered set of targets, rewiring functional networks in cells40. We identified eight isomiRs that were significantly dysregulated in liver cancer; however, only two isomiR-21-5p | ±1 were significantly associated with patients′ survival (Fig. 2b, e). These clinical associations were validated with a series of molecular and functional assays, indicating that isomiRs are not just byproducts of miRNA processing but also functional miRNAs that regulate their targets in the cancer development process. Although isomiRs of pri-miR-21 have been previously detected in other cancers41,42, they appear to be 3′-isomiRs, all with the same seed sequence, rather than 5′-isomiRs.
Because isomiRs differ by only a few nucleotides, examination of individual isomiR abundance and function requires careful attention to the specificity of our experimental techniques. First, RT–qPCR needs sufficient specificity to distinguish between the isomiRs for accurate determination of their abundance. Llorens et al. verified the specificity of 5′-isomiR detection using RT–qPCR with two specific primers43 and we found that the use of only one specific primer could distinguish between isomiRs with different 5′-ends (Fig. 3 and Supplementary Fig. 3). Next, antagomir specificity must be guaranteed for the isomiR functional assay. Many modification methods have been developed and applied to increase antagomir efficiency, but these modifications have lowered specificity44. Nevertheless, because GHR has target sites for both isomiR-21-5p | ±1 and miR-21-5p (Fig. 7e and Supplementary Fig. 7c), the results of our antagomir-based functional assays were mainly derived from the functional effects of isomiR-21-5p | ±1.
Although a handful of isomiRs were dysregulated in our LIHC samples, there should be more oncogenic or tumor-suppressing isomiR candidates in other cancers in which RBPs, such as hnRNPC and U2AF2, are dysregulated. In fact, hnRNPC and U2AF2 had strong eCLIP signals on 4 and 24 pri-miRNAs, respectively, in HepG2 cells (Supplementary Fig. 6b), suggesting that the cross-talk between miRNA processing and RBPs could be more prevalent than we anticipated. Some RBPs involved in miRNA maturation have been previously reported. For example, the DEAD-box RNA helicase subunit DDX17 promotes Drosha-mediated pri-miRNA processing45,46, and SMADs, activated by TGFβ/BMP, recruit the Drosha complex by binding to a conserved sequence in the stem region of approximately 20 miRNAs47,48. HIF interacts with Drosha to regulate pri-miR-215 processing under hypoxic conditions49. However, these studies only focused on the RBP-mediated regulation of Drosha processing efficiency and not specificity. Control of isomiR production by other RBPs requires further examination.
However, although we failed to detect any somatic mutations or RNA editing in pri-miRNAs associated with the production of isomiRs in liver cancer, such features could be present in other cancers. Alterations in cis-acting elements related to Drosha processing specificity can modulate the production ratio of oncogenic and tumor-suppressing isomiRs. In addition, the epitranscriptomic regulator METTL3/14 was previously reported to alter pri-miRNA structures by generating N6-methyladenosine (m6A) marks on RNAs, some of which are likely to affect Drosha processing independently of m6A reader proteins50,51. However, mutations in intrinsic factors are restricted to a few miRNAs in each individual, and somatic mutations, RNA editing, and RNA modifications affecting miRNA processing are sporadically detected. To comprehensively summarize the mutations in cis-acting elements, more samples should be investigated.
hnRNPC and U2AF2 compete for common binding sites, specifically single-stranded structures within polypyrimidine tracts51,52, and regulate pre-mRNA splicing by associating with the spliceosome53. In addition, Agranat-Tamir et al. reported that spliceosomes can interact with microprocessors54. These studies support the possibility of direct competition between hnRNPC and U2AF2 to regulate isomiR-21-5p | ±1 biogenesis. In fact, our analysis of hnRNPC and U2AF2 eCLIP-seq data showed their colocalization in the pri-miR-21 flanking regions (Fig. 5a). The greater effect of hnRNPC on isomiR-21-5p | ±1 biogenesis that we observed (Fig. 5 and Supplementary Fig. 5) could be due to the dominant distribution of poly-(U), providing a stronger affinity for hnRNPC in the upstream flanking region of pre-miR-2152. hnRNPC binds to pri-miR-21 over the basal junction and UG motif, which are thought to be anchored by Drosha16, and its effects on the regulation of the isomiR ratio could occur at any binding site in the 250-nt flanking region of pre-miR-21 because hnRNPC binds to an ~230-nt stretch of RNA30,31,32. However, the molecular mechanism by which hnRNPC regulates miRNA processing needs to be further clarified. There are two possible models: 1) hnRNPC binding to pri-miR-21 could interfere with Drosha binding, or 2) hnRNPC binding to pri-miR-21 could change the pri-miR-21 structure. Additional studies are required to evaluate these possibilities.
We report that isomiR-21-5p | ±1 regulates GHR, possibly acting as a tumor suppressor that is often downregulated in cancers. In fact, the deletion of Akt isoforms was previously observed to reduce the level of Ghr mRNA, mediating HCC progression via the insulin pathway in mice55, which suggests a possible mechanism for the tumor-suppressive function of GHR. The anti-growth effect of treatment with either AS-isomiR-21-5p | +1 or AS-isomiR-21-5p | -1 in all tested cells was phenocopied by treatment with a GHR-expressing plasmid (Supplementary Fig. 8a). Notably, GHR expression was suppressed in most cancers, with a few exceptions in the TCGA dataset (Supplementary Fig. 8b). Among them, GHR expression in LIHC and kidney renal clear cell carcinoma (KIRC) is clinically relevant, with high GHR expression associated with significant positive effects on overall survival but with negative effects in bladder urothelial carcinoma (BLCA), thyroid cancer (THCA), and stomach adenocarcinoma (STAD) (Supplementary Fig. 8c). In particular, GHR was most repressed in liver cancer compared to its expression in non-tumor tissues. The change in GHR expression was further validated with the Catholic_LIHC and Tsinghua_LIHC datasets (Supplementary Fig. 8d). Liver cancer patients with high GHR expression showed better overall prognosis and longer relapse-free survival (Supplementary Fig. 8e). However, the survival rate of patients with low expression of isomiR-21-5p or high expression of GHR dramatically decayed after four years, indicating that the isomiR-21-5p–GHR regulatory axis is no longer sufficient to maintain the benefits to patients in later years. Despite these results, further research is needed to examine whether GHR functions as a tumor suppressor and whether GHR depletion leads to tumor development in vivo.
In conclusion, our study not only sheds light on the biological and clinical importance of isomiRs but also has clinical implications for controlling miRNA and exogenous siRNA processing to produce intended miRNAs and siRNAs in the future.
Data availability
miRNA sequencing data and RNA-seq data were deposited in the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the accession codes GSE174608 and GSE114564. All Python and R codes used in this study are available at the GitHub repository (https://github.com/ParkSJ-91/isomiR).
References
Bartel, D. P. Metazoan microRNAs. Cell 173, 20–51 (2018).
Chiang, H. R. et al. Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev. 24, 992–1009 (2010).
Cloonan, N. et al. MicroRNAs and their isomiRs function cooperatively to target common biological pathways. Genome Biol. 12, R126 (2011).
Tan, G. C. et al. 5’ isomiR variation is of functional and evolutionary importance. Nucleic Acids Res. 42, 9424–9435 (2014).
Salem, O. et al. The highly expressed 5’isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. BMC Genomics 17, 566 (2016).
Han, J. et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18, 3016–3027 (2004).
Denli, A. M., Tops, B. B., Plasterk, R. H., Ketting, R. F. & Hannon, G. J. Processing of primary microRNAs by the Microprocessor complex. Nature 432, 231–235 (2004).
Han, J. et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 125, 887–901 (2006).
Fang, W. & Bartel, D. P. The menu of features that define primary microRNAs and enable de novo design of microRNA genes. Mol. Cell 60, 131–145 (2015).
Roden, C. et al. Novel determinants of mammalian primary microRNA processing revealed by systematic evaluation of hairpin-containing transcripts and human genetic variation. Genome Res. 27, 374–384 (2017).
Zeng, Y., Yi, R. & Cullen, B. R. Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO J. 24, 138–148 (2005).
Ma, H., Wu, Y., Choi, J. G. & Wu, H. Lower and upper stem-single-stranded RNA junctions together determine the Drosha cleavage site. Proc. Natl Acad. Sci. USA 110, 20687–20692 (2013).
Auyeung, V. C., Ulitsky, I., McGeary, S. E. & Bartel, D. P. Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing. Cell 152, 844–858 (2013).
Nguyen, T. A. et al. Functional anatomy of the human microprocessor. Cell 161, 1374–1387 (2015).
Kim, K., Nguyen, T. D., Li, S. & Nguyen, T. A. SRSF3 recruits DROSHA to the basal junction of primary microRNAs. RNA 24, 892–898 (2018).
Kwon, S. C. et al. Molecular basis for the single-nucleotide precision of primary microRNA processing. Mol. Cell 73, 505–518 e505 (2019).
Bofill-De Ros, X. et al. Structural differences between pri-miRNA paralogs promote alternative drosha cleavage and expand target repertoires. Cell Rep. 26, 447–459 e444 (2019).
Macrae, I. J. et al. Structural basis for double-stranded RNA processing by Dicer. Science 311, 195–198 (2006).
MacRae, I. J., Zhou, K. & Doudna, J. A. Structural determinants of RNA recognition and cleavage by Dicer. Nat. Struct. Mol. Biol. 14, 934–940 (2007).
Park, J. E. et al. Dicer recognizes the 5’ end of RNA for efficient and accurate processing. Nature 475, 201–205 (2011).
Gu, S. et al. The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. Cell 151, 900–911 (2012).
Kim, H. et al. Bias-minimized quantification of microRNA reveals widespread alternative processing and 3’ end modification. Nucleic Acids Res. 47, 2630–2640 (2019).
Telonis, A. G. et al. Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. Nucleic Acids Res. 45, 2973–2985 (2017).
Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology 68, 723–750 (2018).
Nam, J. W. et al. Global analyses of the effect of different cellular contexts on microRNA targeting. Mol. Cell 53, 1031–1043 (2014).
Yang, Y. et al. Recurrently deregulated lncRNAs in hepatocellular carcinoma. Nat. Commun. 8, 14421 (2017).
Friedlander, M. R., Mackowiak, S. D., Li, N., Chen, W. & Rajewsky, N. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 40, 37–52 (2012).
Wang, A. G. et al. Gender-dependent hepatic alterations in H-ras12V transgenic mice. J. Hepatol. 43, 836–844 (2005).
Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
Huang, M. et al. The C-protein tetramer binds 230 to 240 nucleotides of pre-mRNA and nucleates the assembly of 40S heterogeneous nuclear ribonucleoprotein particles. Mol. Cell Biol. 14, 518–533 (1994).
McAfee, J. G., Soltaninassab, S. R., Lindsay, M. E. & LeStourgeon, W. M. Proteins C1 and C2 of heterogeneous nuclear ribonucleoprotein complexes bind RNA in a highly cooperative fashion: support for their contiguous deposition on pre-mRNA during transcription. Biochemistry 35, 1212–1222 (1996).
McCloskey, A., Taniguchi, I., Shinmyozu, K. & Ohno, M. hnRNP C tetramer measures RNA length to classify RNA polymerase II transcripts for export. Science 335, 1643–1646 (2012).
Agarwal, V., Bell, G. W., Nam, J. W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4, e05005 (2015).
Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20 (2005).
Krek, A. et al. Combinatorial microRNA target predictions. Nat. Genet. 37, 495–500 (2005).
Brennecke, J., Stark, A., Russell, R. B. & Cohen, S. M. Principles of microRNA-target recognition. PLoS Biol. 3, e85 (2005).
Kim, D. et al. General rules for functional microRNA targeting. Nat. Genet. 48, 1517–1526 (2016).
Neilsen, C. T., Goodall, G. J. & Bracken, C. P. IsomiRs-the overlooked repertoire in the dynamic microRNAome. Trends Genet. 28, 544–549 (2012).
McCall, M. N. et al. Toward the human cellular microRNAome. Genome Res. 27, 1769–1781 (2017).
Manzano, M., Forte, E., Raja, A. N., Schipma, M. J. & Gottwein, E. Divergent target recognition by coexpressed 5’-isomiRs of miR-142-3p and selective viral mimicry. RNA 21, 1606–1620 (2015).
Telonis, A. G. & Rigoutsos, I. Race disparities in the contribution of miRNA isoforms and tRNA-derived fragments to triple-negative breast cancer. Cancer Res. 78, 1140–1154 (2018).
Koppers-Lalic, D. et al. Noninvasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget 7, 22566–22578 (2016).
Llorens, F. et al. A highly expressed miR-101 isomiR is a functional silencing small RNA. BMC Genomics 14, 104 (2013).
Lennox, K. A. & Behlke, M. A. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 18, 1111–1120 (2011).
Mori, M. et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 156, 893–906 (2014).
Moy, R. H. et al. Stem-loop recognition by DDX17 facilitates miRNA processing and antiviral defense. Cell 158, 764–777 (2014).
Davis, B. N., Hilyard, A. C., Lagna, G. & Hata, A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454, 56–61 (2008).
Davis, B. N., Hilyard, A. C., Nguyen, P. H., Lagna, G. & Hata, A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell 39, 373–384 (2010).
Hu, J. et al. MiR-215 is induced post-transcriptionally via HIF-drosha complex and mediates glioma-initiating cell adaptation to hypoxia by targeting KDM1B. Cancer Cell 29, 49–60 (2016).
Alarcon, C. R., Lee, H., Goodarzi, H., Halberg, N. & Tavazoie, S. F. N6-methyladenosine marks primary microRNAs for processing. Nature 519, 482–485 (2015).
Liu, N. et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 518, 560–564 (2015).
Zarnack, K. et al. Direct competition between hnRNP C and U2AF65 protects the transcriptome from the exonization of Alu elements. Cell 152, 453–466 (2013).
Wahl, M. C., Will, C. L. & Luhrmann, R. The spliceosome: design principles of a dynamic RNP machine. Cell 136, 701–718 (2009).
Agranat-Tamir, L., Shomron, N., Sperling, J. & Sperling, R. Interplay between pre-mRNA splicing and microRNA biogenesis within the supraspliceosome. Nucleic Acids Res. 42, 4640–4651 (2014).
Wang, Q. et al. Spontaneous hepatocellular carcinoma after the combined deletion of Akt isoforms. Cancer Cell 29, 523–535 (2016).
Acknowledgements
We thank all Bioinformatics and Genomics (BIG) lab members for inspiring comments and discussions, Professor V. Narry Kim of Seoul National University for critical discussions and resources, and Professor Paul N. Valdmanis for critical reading. This work was supported by the Bio & Medical Technology Development Program and the Basic Research Program of the National Research Foundation (NRF) funded by the Korean government, MSIT [NRF-2020R1A4A1018398 to J.W.N., 2021M3A9I4024452 to J.W.N., 2021R1A6A3A13046250 to S.P., 2021R1A2C3005835 to J.W.N., 2017R1A2B3002989 to S.W.N., and 2021M3E5E7021893 to S.W.N.]. The results shown in this study are in part based on data generated by the TCGA Research Network: https://www.cancer.gov/tcga.
Author information
Authors and Affiliations
Contributions
S.J.P. performed bioinformatic analyses; H.D.Y. performed wet experiments; S.J.P. and J.W.S. contributed to raw data processing and data curation; S.J.P., H.D.Y., J.W.N., and S.W.N. contributed to writing the manuscript; S.W.N. and J.W.N. supervised the project; S.J.P. and J.W.N. conceived the idea.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Park, S., Yang, H.D., Seo, JW. et al. hnRNPC induces isoform shifts in miR-21-5p leading to cancer development. Exp Mol Med 54, 812–824 (2022). https://doi.org/10.1038/s12276-022-00792-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s12276-022-00792-2
- Springer Nature Limited
This article is cited by
-
CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis
Molecular Cancer (2024)
-
New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma
Acta Pharmacologica Sinica (2024)
-
One locus, several functional RNAs—emerging roles of the mechanisms responsible for the sequence variability of microRNAs
Biologia Futura (2023)